Capecitabine as adjuvant treatment for stage III colon cancer. 30. Mai 2005 Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., Husseini, F., Jodrell, D., Koralewski, P., Kröning, H., Maroun, J., Marschner, N., McKendrick, J., Pawlicki, M., Rosso, R., Schüller, J., Seitz, J.-F., Stabuc, B., Tujakowski, J., Van Hazel, G., Zaluski, J., Scheithauer, W., 2005. N Engl J Med 352, 2696–704. doi:10.1056/NEJMoa043116 Abstract Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Behringer, D., Kindler, M., Messmann, H., Boeck, H.-P., Greinwald,… Weiterlesen Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Twelves, C.J., 2006. Clin Colorectal Cancer 6, 278–287. Abstract… Weiterlesen